IRVINE, Calif. & BENGALURU, India--(BUSINESS WIRE)--Feb. 25, 2016--
Masimo
(NASDAQ: MASI) announced today that Manipal
Hospitals is the first hospital in India to install Masimo Patient
SafetyNet™, a remote monitoring and clinician notification system.
This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20160225005616/en/
“With Patient SafetyNet, we are now able to monitor a certain set of
patients 24x7,” said Gopal Devanahalli, Chief Operating Officer of
Manipal Hospitals. “One of the key features of this system is its
proprietary Signal Extraction Technology (SET®) that helps significantly
reduce false alarms.”
“This is the technological advancement that we were awaiting,” said Dr.
Nagendra Swamy SC, MD, Senior President, Manipal Health Enterprises, and
Group Medical Director & Chairman, Quality Council, Manipal Health
Enterprises. “The technology will notify the hospital team when there
are signs of deterioration and allow our patients to be monitored even
though the nurse is not physically in the room with them.”
Masimo Patient SafetyNet works in conjunction with Masimo bedside
monitors which provide continuous and noninvasive monitoring of oxygen
saturation (SpO2), pulse rate, respiration rate, and other
parameters. When changes occur in the measured values, which may
indicate deterioration in the patient’s condition, in addition to
bedside alarms, Masimo Patient SafetyNet automatically sends wireless
alerts directly to clinicians. Continuous patient surveillance with
Masimo Patient SafetyNet has been shown to reduce the need for rescue
events and intensive care unit transfers in hospitals and, as a result,
can reduce costs related to these events.1,2
“Manipal Hospitals treats close to 2 million patients annually and
needed a monitoring system that they could trust would work in
challenging patient populations,” said Joe Kiani, Founder and CEO of
Masimo. “We are excited to see this shift internationally with more and
more hospitals worldwide recognizing the importance of integrating
remote monitoring systems as a part of their patient safety initiatives.”
@MasimoInnovates
| #Masimo
1 Taenzer A.H., Pyke J.B., McGrath S.P., Blike G.T. Anesthesiology.
2010 Feb;112(2):282-7.
2 Taenzer A, Blike G, McGrath S, Pyke J, Herrick M, Renaud C, Morgan J.
“Postoperative Monitoring - The Dartmouth Experience.” Anesthesia
Patient Safety Foundation Newsletter Spring-Summer 2012. Available online.
About Manipal Hospitals
As a pioneer in healthcare, Manipal Hospitals is among the largest
hospital networks in India, serving over 2 million patients annually.
Its focus is to develop an affordable tertiary care multispecialty
healthcare framework through its entire multispecialty delivery spectrum
and further extend it to homecare. With its flagship quaternary care
facility located in Bengaluru, India, 8 tertiary care, 7 secondary care
and 2 primary care clinics spread across India and abroad, today Manipal
Hospitals successfully operates and manages 5,200+ beds. Manipal
Hospitals provides comprehensive curative and preventive care for a
multitude of patients from across the globe. Manipal Hospitals is the
first in India to be awarded accreditation by the AAHRPP for ethical
standards in clinical research activities. It is also NABL, NABH and ISO
certified. Manipal Hospitals is also the most respected hospital company
in India and the most patient recommended hospital in India by consumer
survey.
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care by taking noninvasive monitoring to new sites
and applications. In 1995, the company debuted Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry, which has been
shown in multiple studies to significantly reduce false alarms and
accurately monitor for true alarms. The benefits of Masimo SET® have
been proven in more than 100 independent and objective studies and it is
estimated to be used on more than 100 million patients in leading
hospitals and other healthcare settings around the world. In 2005,
Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing
noninvasive and continuous monitoring of blood constituents that
previously could only be measured invasively, including total hemoglobin
(SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and more recently, Pleth Variability Index
(PVI®) and Oxygen Reserve Index (ORI™), in addition to SpO2, pulse rate,
and perfusion index (PI). In 2014, Masimo introduced Root®, an intuitive
open architecture patient monitoring and connectivity platform designed
to speed the pace of innovation and reduce the cost of care. Masimo is
also taking an active leadership role in mHealth with products such as
the Radius-7™ wearable patient monitor and the MightySat™ fingertip
pulse oximeter. Additional information about Masimo and its products may
be found at www.masimo.com.
Forward-Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, among others, statements regarding the potential
effectiveness of Masimo Patient SafetyNet™. These forward-looking
statements are based on current expectations about future events
affecting us and are subject to risks and uncertainties, all of which
are difficult to predict and many of which are beyond our control and
could cause our actual results to differ materially and adversely from
those expressed in our forward-looking statements as a result of various
risk factors, including, but not limited to: risks related to our
assumptions regarding the repeatability of clinical results or studies;
risks related to our belief that Masimo's unique noninvasive measurement
technologies and monitoring system solutions, including Masimo Patient
SafetyNet, contribute to positive clinical outcomes and patient safety;
risks related to our belief that Masimo noninvasive medical
breakthroughs provide cost-effective solutions with comparable accuracy
and unique advantages, including: immediate and continuous results that
enable earlier treatment without causing invasive trauma in all patients
and in every clinical situation, including the dental setting; as well
as other factors discussed in the "Risk Factors" section of our most
recent reports filed with the Securities and Exchange Commission
("SEC"), which may be obtained for free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160225005616/en/
Source: Masimo
Masimo
Media:
Irene Paigah, +1-858-859-7001
irenep@masimo.com
or
Manipal
Hospitals
Media:
Anjana Chandran, +91-988-627-8400
anjana.chandran@manipalhospitals.com